The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Share News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 422.50
Bid: 415.00
Ask: 430.00
Change: -5.00 (-1.17%)
Spread: 15.00 (3.614%)
Open: 427.50
High: 422.50
Low: 419.00
Prev. Close: 427.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disinfectant Demand Pushes Up Tristel's Interim Profit, Hikes Dividend

Mon, 22nd Feb 2021 10:59

(Alliance News) - Tristel PLC on Monday reported a higher half-year profit, with overseas revenue particularly high, as the pandemic lifted demand for disinfectants.

The company, which makes infection prevention and contamination control products, posted a GBP3.1 million pretax profit for the six months ended December 31, up 11% from GBP2.8 million the year before.

Revenue increased 15% to GBP16.8 million from GBP14.6 million, including an 8% rise in UK revenue thanks to an 18% rise in cash surface disinfection revenue to GBP1.5 million from GBP800,000.

Overseas revenue increased by 20% to GBP10.0 million from GBP8.3 million, including a 19% rise in Tristel medical device decontamination revenue to GBP8.7 million plus a 67% rise in cash surface disinfection revenue to GBP500,000.

"Tristel product sales in all countries have been adversely affected as patient examinations have been deferred. Cache product sales have been positively impacted because hospitals rushed to purchase any type of disinfectant. During the second half of 2020 this phenomenon came to an end and now we are observing a more considered approach to the selection of surface disinfectants," explained Chair Bruno Holthof.

The company lifted its interim dividend per share by 12% to 2.62 pence from 2.34p a share the year before.

Chief Executive Paul Swinney said: "The second half will be the third consecutive six-month period to be impacted by the pandemic. Unlike the previous two halves, we have started this one in lockdown in many of our key markets. Sales of our medical device disinfectants during the first seven weeks of 2021 are lower than budget due to the impact of Covid-19 on patient examinations. We are very confident that by the end of calendar 2021, the ENT, gynaecology, urology, cardiology, and ophthalmology departments where our products are used will have returned to pre-pandemic levels of activity. Whether this will happen in the UK and Europe before our June year-end is unclear at present.

"However, the growth prospects for the group are as strong as ever and we look to the future with confidence."

Shares in Tristel were up 0.1% at 600.55p in London on Monday morning.

By Anna Farley; annafarley@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
9 Sep 2010 14:44

London afternoon: ARM gives Footsie a hand

Mining stocks continue to drive the market's advance, despite metal prices falling back as concerns grow about the Chinese authorities' determination to cool off the economy, with the latest report from the People's Republic suggesting that the government is set to introduce measures to curb propert

Read more
28 Jun 2010 16:33

Non-exec's firm cashes in at Lancashire

Lancashire Holdings non-executive director Barry Volpert is chief executive of private equity firm Crestview, which has raised more than £4.7m from the sale of shares in the property, aviation and marine insurer. The share prices of the five separate disposals varied from 497p to just over 500p. C

Read more
8 Mar 2010 09:00

Tristel profits climb after acquisition

Disinfectant supplier Tristel posted a rise in turnover and profits in the six months to December 31 as it proceeded with the integration of a portfolio of products it acquired from Medichem. Pre-tax profits climbed to £656,000 from £469,000 over the same period the previous year as revenues climbe

Read more
4 Dec 2009 16:26

Ultra boss sells

Ultra Electronics chief executive Douglas Caster has generated £5.85m from the sale of just over two-fifths of his shareholding in the defence electronics supplier. He states in the announcement that the sale was for "family and tax planning reasons". Caster has also transferred his remaining 63

Read more
9 Nov 2009 11:43

Small caps round-up: Nautical Petroleum, ThirdForce, Allied Gold...

Oil group Nautical Petroleum reported 'significant progress' in its asset portfolio in the year to June 30 and said it expects its assets to rise in value once they move into the execution stage. Pre-tax losses for the year totalled £6.63m, compared with £4.52m the previous year. Shares in e-learn

Read more
12 Oct 2009 15:49

Comment: Tristel looks to clean up overseas

Tristel chief executive Paul Swinney described the infection and contamination control company's results as 'good, if not spectacular' but his modesty contrasts with his excitement about the prospect of overseas expansion. In the year to June 30, Tristel, whose products are used to combat infection

Read more
12 Oct 2009 07:17

Tristel ups divi as profits climb

The continuing struggle to keep infections such as Clostridium difficile out of hospitals helped disinfectant supplier Tristel post a rise in turnover and profits in the year to June 30. Tristel, whose products are based on chlorine dioxide chemistry, said revenues climbed to £6.8m from £6m over th

Read more
3 Jul 2009 17:08

Tristel chairman sells

Francisco Soler, non-executive chairman of Tristel, sold £315,680 worth of shares in the disinfectant supplier to satisfy institutional demand following the group's oversubscribed placing. Soler disposed of 769,951 shares in Tristel at 41p each as the group raised £1m to part finance the purchase

Read more
3 Jul 2009 07:47

Tristel gets £1m towards portfolio purchase

Disinfectant supplier Tristel has raised £1m to part finance the purchase of a portfolio of infection control products for between £2.15m and £2.4m. It has placed 2.7m shares at 41p each, which will help buy intellectual property and manufacturing rights from Medichem International. The placing was

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.